Baker Bros. Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Baker Bros. Advisors’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-88,026	Closed	-$970K	–	121
2020 Q1	$970K	Sell	88,026 -39,210	-31%	-$732K	0.01%	100
2019 Q4	$3.36M	Hold	127,236	–	–	0.02%	80
2019 Q3	$2.9M	Hold	127,236	–	–	0.02%	79
2019 Q2	$3.9M	Hold	127,236	–	–	0.03%	67
2019 Q1	$2.11M	Hold	127,236	–	–	0.01%	79
2018 Q4	$2.44M	Hold	127,236	–	–	0.02%	69
2018 Q3	$6.65M	Sell	127,236 -42,256	-25%	-$2.3M	0.04%	64
2018 Q2	$7.37M	Hold	169,492	–	–	0.06%	63
2018 Q1	$6.28M	Buy	+169,492	New	+$4.52M	0.05%	70

Other funds holding GTHX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Baker Bros. Advisors's GTHX Position: Q2 2020 in Review

Baker Bros. Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2020, closing a stake of 88,026 shares — an estimated $970K sold.

Baker Bros. Advisors first reported a position in GTHX in Q1 2018 and held it in 9 quarters. The position peaked at $7.37M in Q2 2018. 100 funds tracked by Wall St. Rank hold GTHX as of Q2 2020.

Baker Bros. Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Baker Bros. Advisors sold 88,026 G1 Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $970K.
Baker Bros. Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2018 and held it in 9 quarters.
Baker Bros. Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $7.37M in Q2 2018.
100 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Baker Bros. Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.